Jan 11, 2024 Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting Learn More
Jan 8, 2024 Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia Learn More
Jan 3, 2024 Cellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024 Learn More
Dec 19, 2023 Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation Learn More